Boehringer Ingelheim
Overview
Boehringer Ingelheim is a research-driven pharmaceutical company that invests in therapeutic innovation through its corporate venture capital arm, the Boehringer Ingelheim Venture Fund (BIVF). The fund focuses on early-stage and seed investments in areas like immuno-oncology, regenerative medicine, infectious diseases, and digital health.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Tacalyx | Apr 2026 | Seed | Co-investor |
| Click Therapeutics | Apr 2026 | Series D | Lead |
| Centauri Therapeutics Limited | Feb 2026 | Series A Extension | Co-investor |
| Rectify Pharma | Dec 2025 | Strategic | Co-investor |
| ArrePath | Jun 2025 | VC Round | Lead |
Key People
Sebastian Kreuz
Executive Director Investment Manager (BI Venture Fund)
Ajith A
Speciality Therapeutic Partner
Daphne Openda
People Partner- Southern Africa OPU
Malcolm Eddie
Head Of Global Support - CRO Strategic Partner Management
Nardjess Nawel Laroussi
Specialty Care Therapy Partner
Swati Choudhary
Learning Partner
Edwin Osas
Senior Principal Consultant CIO Advisory
Anupama Roy
Associate Director- Project & Partner Management, Global Pharmacovigilance
Ali M. YOUSIF
Principal Scientist Head Of Peptide Laboratory
Annett Keller
Senior Principal Statistician, CMC Statistics
Aradhana ‘Ara’ Gupta
Sr. Principal Pathologist
Azar Omrani
Principal Scientist-Head Of Laboratory
Benno Ehrl
Principal Scientist - Head Of Laboratory
Di Feng
Senior Principal Scientist, Computational Biology, Computational Biology Expert Lead
Eric Simon
Senior Principal Scientist, Computational Biology, Principal Scientist, Computational Biology Bei Boehringer Ingelheim
Frank Buettner
Senior Principal Scientist - Head Of Laboratory
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
